THERAPY DOSSIER · th-a0faabc26676

Bone marrow-derived MSCs transduced with adenoviral scleraxis (Ad-Scx)

Biologic · Gene-modified cell therapy; no ChEMBL entity. No ClinicalTrials.gov record of scleraxis-transduced MSCs.

Evidence & regulatory context

Mechanism: Gene-modified cell therapy; no ChEMBL entity. No ClinicalTrials.gov record of scleraxis-transduced MSCs.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21335341 ↗2011Reported benefit

Bone marrow-derived mesenchymal stem cells transduced with scleraxis improve rotator cuff healing in a rat model.

RatOtherLewisn = 60Local implantation in fibrin glue carrierAt time of repair

Model: Unilateral supraspinatus tendon detachment and repair (rotator cuff)

Scleraxis-transduced MSCs increased fibrocartilage and improved biomechanical strength of the healing tendon-bone interface versus MSCs alone at early time points.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…